Effect of Cimetidine on Survival after gastric cancer

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group.

Detaljer

Författare
  • Hanne Tonnesen
  • Steffen Bülow
  • Kaj Fischerman
  • Allan Hjortrup
  • Vilhelm Møller Pedersen
  • Lars Bo Svendsen
  • Ulrich Knigge
  • Peter Damm
  • Peter Hesselfeldt
  • Ib Krogh Pedersen
  • Ole Julius Siemssen
  • Poul Martin Christiansen
Externa organisationer
  • Hvidovre Hospital
  • Copenhagen University Hospital
  • University Hospital Amager
  • Gentofte Hospital
  • Bispebjerg Hospital
  • Kommunehospitalet
  • Frederiksberg Hospital
  • Glostrup Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Sidor (från-till)990-992
Antal sidor3
TidskriftThe Lancet
Volym332
Utgåva nummer8618
StatusPublished - 1988 okt 29
PublikationskategoriForskning
Peer review utfördJa
Externt publiceradJa